Collegium Pharmaceutical (COLL) Stock Rating Upgraded by BidaskClub

BidaskClub upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a hold rating to a buy rating in a research note issued to investors on Wednesday.

A number of other research firms have also recently issued reports on COLL. TheStreet upgraded shares of Collegium Pharmaceutical from a d+ rating to a c rating in a research note on Wednesday, March 7th. Piper Jaffray set a $33.00 target price on shares of Collegium Pharmaceutical and gave the stock a buy rating in a research note on Tuesday, January 23rd. HC Wainwright raised their target price on shares of Collegium Pharmaceutical from $21.00 to $33.00 and gave the stock a buy rating in a research note on Thursday, March 8th. William Blair restated an outperform rating on shares of Collegium Pharmaceutical in a research note on Thursday, March 8th. Finally, Zacks Investment Research cut shares of Collegium Pharmaceutical from a buy rating to a hold rating in a research note on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $29.17.

How to Become a New Pot Stock Millionaire

NASDAQ COLL opened at $25.55 on Wednesday. Collegium Pharmaceutical has a 52-week low of $7.37 and a 52-week high of $29.90.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Wednesday, March 7th. The specialty pharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.02. The company had revenue of $10.79 million during the quarter, compared to analysts’ expectations of $9.88 million. Collegium Pharmaceutical had a negative net margin of 262.91% and a negative return on equity of 73.00%. The business’s quarterly revenue was up 728.4% on a year-over-year basis. research analysts forecast that Collegium Pharmaceutical will post -0.76 earnings per share for the current fiscal year.

In related news, Chairman Michael Thomas Heffernan sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, January 23rd. The shares were sold at an average price of $25.01, for a total transaction of $500,200.00. Following the transaction, the chairman now directly owns 535,395 shares of the company’s stock, valued at $13,390,228.95. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Alison B. Fleming sold 6,928 shares of the firm’s stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $19.07, for a total transaction of $132,116.96. Following the transaction, the insider now directly owns 32,651 shares in the company, valued at $622,654.57. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 46,928 shares of company stock worth $1,082,317. 25.76% of the stock is owned by insiders.

A number of large investors have recently added to or reduced their stakes in COLL. Citadel Advisors LLC increased its position in Collegium Pharmaceutical by 773.8% during the third quarter. Citadel Advisors LLC now owns 544,033 shares of the specialty pharmaceutical company’s stock worth $5,707,000 after acquiring an additional 481,771 shares during the period. First Manhattan Co. bought a new position in Collegium Pharmaceutical during the fourth quarter worth about $8,606,000. Deutsche Bank AG increased its position in Collegium Pharmaceutical by 528.0% during the fourth quarter. Deutsche Bank AG now owns 414,115 shares of the specialty pharmaceutical company’s stock worth $7,643,000 after acquiring an additional 348,169 shares during the period. Cortina Asset Management LLC bought a new position in Collegium Pharmaceutical during the fourth quarter worth about $5,476,000. Finally, Macquarie Group Ltd. increased its position in Collegium Pharmaceutical by 21.5% during the fourth quarter. Macquarie Group Ltd. now owns 1,616,117 shares of the specialty pharmaceutical company’s stock worth $29,833,000 after acquiring an additional 286,138 shares during the period. 86.39% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by WKRB News and is owned by of WKRB News. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.wkrb13.com/2018/04/01/collegium-pharmaceutical-coll-stock-rating-upgraded-by-bidaskclub.html.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply